API | tandutinib

tandutinib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
InChIKey: UXXQOJXBIDBUAC-UHFFFAOYSA-N
Mol. Mass: 562.72
ALogP: 5.03 Partition coefficient
ChEMBL Molecule:
tandutinib

More Chemistry

Pharmacology

Mechanisms of Action:
- Platelet-derived growth factor receptor beta (Homo sapiens) ^UniProt
- Mast/stem cell growth factor receptor Kit (Homo sapiens) ^UniProt
- Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

4-(6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide | ct53518 | ct 53518 | ct-53518 | mln-0518 | mln518 | mln 518 | mln-518 | tandutinib

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Astrocytoma (Phase 2)

Brain Neoplasms (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 2)

Glioblastoma (Phase 2)

Gliosarcoma (Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 2)

Oligodendroglioma (Phase 2)

Pain (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue